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Abstract
Hemin accumulates in intracerebral hematomas and may contribute to cell injury in adjacent
tissue. Despite its relevance to hemorrhagic CNS insults, very little is known about hemin
trafficking by neural cells. In the present study, hemin uptake and release were quantified in
primary murine cortical cultures, and the effect of the hemin-binding compound deferoxamine
(DFO) was assessed. Net uptake of 55Fe-hemin was similar in mixed neuron-glia, neuron, and glia
cultures, but was 2.6–3.6-fold greater in microglia cultures. After washout, 40–60% of the isotope
signal was released by mixed neuron-glia cultures into albumin-containing medium within 24
hours. Inhibiting hemin breakdown with tin protoporphyrin IX (SnPPIX) had minimal effect,
while release of the fluorescent hemin analog zinc mesoporphyrin was quantitatively similar to
that of 55Fe-hemin. Isotope was released most rapidly by neurons (52.2±7.2% at 2 hours),
compared with glia (15.6±1.3%) and microglia (17.6±0.54%). DFO did not alter 55Fe-hemin
uptake, but significantly increased its release. Mixed cultures treated with 10 μM hemin for 24
hours sustained widespread neuronal loss that was attenuated by DFO. Concomitant treatment
with SnPPIX had no effect on either enhancement of isotope release by DFO or neuroprotection.
These results suggest that in the presence of a physiologic albumin concentration, hemin uptake by
neural cells is followed by considerable extracellular release. Enhancement of this release by DFO
may contribute to its protective effect against hemin toxicity.
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Introduction
Hemin is released from methemoglobin after an intracerebral hemorrhage, and reaches
micromolar concentrations in the hematoma [1]. Although it is a lipophilic compound that
can directly intercalate into the membranes of adjacent cells, recent evidence indicates that
its uptake is regulated at least in part by the action of one or more transport proteins [2–4].
In excess, hemin is a potent neurotoxin that directly catalyzes free radical chain reactions
[5]. Its breakdown by the heme oxygenase (HO) enzymes releases iron, which may further
increase oxidative stress if not rapidly sequestered or exported [6].
Despite its likely relevance to hemorrhagic CNS injuries, hemin trafficking by neural cells
has not been intensively investigated. In vitro experiments using non-neural cell lines
indicate that hemin loading is followed by substantial export over the following few hours
*Corresponding Author: Telephone: 215-955-2695; FAX: 215-923-6225, Raymond.Regan@jefferson.edu.
Declaration of Interest
This study was supported by a grant from the National Institutes of Health (NS079500) to R.F.R. The authors have no financial or
consulting interests which could influence this work.
NIH Public Access
Author Manuscript
Free Radic Res. Author manuscript; available in PMC 2015 February 01.
Published in final edited form as:













[7,8]. This process is facilitated by extracellular albumin or hemopexin, which are acceptor
proteins for the putative cell membrane hemin exporters that have been identified to date
[8,9]. Loss of this export capacity markedly increases cellular vulnerability to exogenous
hemin [10], suggesting that it is an important defense against hemin toxicity. This key
observation raises the possibility that enhancing hemin export may also be beneficial after
CNS hemorrhage, provided that hemin trafficking is similar in cells of neural origin.
However, quantitative data about hemin export in neurons, astrocytes, and microglia are
completely lacking. Furthermore, no low molecular weight pharmaceuticals that accelerate
hemin loss from neural cells have been identified to date.
In the present study, we first tested the hypothesis that primary cultured neural cells release
hemin into the extracellular space within hours of uptake. We subsequently tested the
hypothesis that hemin release could be enhanced by deferoxamine (DFO), a chelator with




Primary cultures containing neurons only or mixed neurons and glia were prepared in 24-
well plates from fetal mice (gestational age 14–16 days) following previously published
methods [13,14]. Glial cultures (predominantly astrocytes, >90% GFAP+) were prepared
from 2–3 day postnatal mice using a similar protocol [13]. Microglial cultures were prepared
by harvesting microglial cells from confluent mixed glial cultures growing in 80 cm2 flasks
(Nunc 153732) by shaking, also as previously described [15]. All procedures using animals
for culture preparation were approved by the Thomas Jefferson University Institutional
Animal Care and Use Committee.
Quantification of hemin and zinc mesoporphyrin uptake and release
Hemin trafficking was studied using 55Fe-hemin (Perkin Elmer, Waltham, MA, USA) or
zinc mesoporphyrin (ZnMP, Frontier Scientific, Logan, UT, USA). The latter is a
fluorescent hemin analog that has previously been validated as a surrogate for hemin in
uptake and export studies [8,16]. Cultures were washed free of serum and were then placed
into uptake medium containing Minimal Essential Medium (MEM) with 10 mM glucose
(MEM10), 0.67 mg/ml bovine serum albumin (BSA), and 100 μg/ml apotransferrin. The
albumin concentration used was similar to that observed in cerebrospinal fluid after
hemorrhagic stroke [17]; apotransferrin was added to prevent iron-mediated injury [18].
Loading concentrations and exposure durations for 55Fe-hemin (5 μM x 2h, 0.38μCi/ml) and
ZnMP (1 μM x 0.5h) were determined from preliminary experiments that demonstrated that
they were nontoxic in this culture medium. After incubation at 37°C for the defined interval,
cultures were washed once with 500 μl MEM10 containing 1mg/ml BSA, followed by three
additional washes with 500 μl MEM10 alone. Cells were then either immediately lysed by
treatment with 0.1% Triton X-100 or were placed into release medium that was identical to
uptake medium except for the absence of 55Fe-hemin and ZnMP. Medium was collected at
defined intervals; cells were then washed and lysed as described above. In some
experiments, DFO (Sigma-Aldrich, St. Louis, MO, USA), 2,2′-dipyridyl (DP, Sigma-
Aldrich) or tin protoporphyrin IX (SnPPIX, Frontier Scientific) were present in the uptake or
release medium. After quantification of medium and lysate radioactivity by liquid
scintillation counting or fluorescence measurement (Ex 410 nm, Em 580 nm), the 55Fe-
hemin or ZnMP content was calculated, and was then normalized to culture protein (BCA
assay). Net uptake is defined as uptake minus release (i.e. export or extraction from
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membranes) during the incubation period. Net release is defined as export or extraction after
washout minus re-uptake prior to cell lysis.
Neurotoxicity assay
Mixed neuron-glia cultures were washed free of serum and then were treated with unlabeled
hemin (Frontier Scientific) alone or with study drugs in MEM10 containing 0.67 mg/ml
BSA and 100 μg/ml apotransferrin. After exposure for 24 hours, culture medium (25 μl) was
sampled; cell death was then quantified by lactate dehydrogenase (LDH) assay [19]. In other
experiments, cultures were treated with unlabeled hemin for 2 hours using the same protocol
described above for uptake and release experiments; study drugs were then added after
hemin washout, and medium was sampled for LDH activity 24 h later. The mean LDH value
in the medium of sister cultures exposed to washes only was subtracted from all values to
yield the signal that was due to hemin toxicity, following the protocol of Koh and Choi [20].
In order to facilitate comparison of cell death in cultures with varying neuronal densities, all
LDH values were normalized to those in sister cultures treated with 300 μM N-methyl-D-
aspartate (NMDA); this treatment kills all neurons.
Statistical analysis
Data were analyzed by one-way ANOVA, followed by the Bonferroni multiple comparisons
test to assess differences between three or more experimental groups. Differences between
two groups were assessed with an unpaired t-test.
Results
Hemin is released from cortical cells
In initial experiments, hemin release was quantified at defined intervals after loading, using
mixed cultures containing both neurons and glia. Approximately one quarter of the isotope
signal was present in the medium at two hours after 55Fe-hemin washout, and 40–60% by 24
hours (Fig 1 A, B). In order to determine if blocking cell hemin breakdown would alter the
extracellular signal, additional experiments were conducted in the presence of the HO
inhibitor tin protoporphyrin IX (SnPPIX) in both the uptake and release media. At
concentrations that inhibit hemin breakdown in neural cells [21], SnPPIX had no effect on
the extracellular 55Fe signal at 4 hours, but did reduce it slightly (~10%) at 24 hours at the
highest concentration tested (Fig. 1B). The release of the fluorescent hemin analog ZnMP
[8,16] from these cultures at 24 hours was quantitatively similar to that of 55Fe-hemin,
although ZnMP release proceeded somewhat more rapidly on a percentage basis (Fig. 1C).
55Fe-hemin uptake and release were next compared in different neural cell populations (Fig.
2). Uptake was similar in cultures containing neurons, glia (>90% GFAP+), or a mixture of
neurons and glial cells. However, it was 2.6–3.6-fold greater in cultures containing only
microglia (P < 0.001 vs. other conditions). After 55Fe-hemin washout, its release from cells
proceeded most rapidly in cultures containing only neurons, with over half detected in the
medium at 2 hours, and over 70% at 24 hours. In contrast, pure microglial cultures released
only about one-sixth of 55Fe-hemin at 2 hours, and only ~40% by 24 hours.
Effect of DFO on hemin uptake and release
DFO binds hemin by interacting with its iron moiety, and is the only pharmaceutical
described to date that increases cellular hemin release [11,12]. We hypothesized that this
compound, which is protective in models of CNS hemorrhage [22,23] would reduce hemin
uptake by neural cells and increase its release. These experiments were conducted in mixed
neuron/glia cultures, which may be more relevant to conditions in the intact CNS than
cultures containing only a single cell population. Contrary to our hypothesis, DFO had no
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effect on net hemin uptake, but it increased release into the culture medium by
approximately 60% in the presence of BSA (Fig. 3A). 2,2′-dipyridyl, an iron chelator that
increases export of nonheme iron in this culture system [24], had no effect on either hemin
uptake or release. 55Fe-hemin release was diminished in medium lacking BSA (58.8±4.4
pmol/mg protein vs. 129.5± 7.8 pmol/mg protein, P < 0.001, Figs. 3A,B), consistent with
prior reports that albumin enhances hemin export [8,9]. DFO increased hemin release in a
concentration-dependent fashion between 1.0 and 100 μM in BSA-free medium, with a 2.5-
fold increase at the latter concentration (Fig. 3B). Enhancement of isotope release into the
medium was not significantly altered by concomitant treatment with SnPPIX to inhibit
hemin breakdown by the heme oxygenases (Fig. 3C).
Deferoxamine protects neurons from hemin toxicity
In mixed cultures treated continuously with hemin 10 μM for 24 hours, widespread neuronal
death was observed without injury to the glial monolayer, consistent with our prior
observation that neurons are selectively vulnerable to hemin in these cultures [25]. Cell loss
was decreased by over 60% by concomitant DFO treatment (Fig. 4A), and was not reversed
by the addition of SnPPIX to inhibit hemin breakdown and iron release. When cultures were
treated with higher concentrations of hemin without DFO for only 2 hours, cell death was
observed over the following 24 hours that was also attenuated when DFO was added to the
release medium only (Fig. 4B).
Discussion
This study provides the first quantitative data about hemin trafficking by primary cells of
CNS origin. In the presence of albumin as a physiological carrier protein, net hemin uptake
in neuron, glia (primarily astrocyte), and neuron-glia cultures was similar, but it was
significantly greater in pure microglia cultures. After washout, neurons rapidly released
hemin, while microglia retained more hemin than other cell types. These observations
suggest that hemin scavenging may be a key protective function of microglia after CNS
hemorrhage that complements their established role in erythrophagocytosis [26].
Direct interaction of DFO with hemin was first reported by Baysal et al. [12] in studies
investigating hemin-induced hemolysis. They reported that the DFO binding affinity for
hemin was sufficient to remove it from erythrocyte ghost membranes. Hemolysis was
reduced in a concentration-dependent fashion at a DFO:hemin molar ratio exceeding 2:1,
while other iron chelators and ferrioxamine (DFO-Fe3+ complexes) were ineffective.
Binding of hemin by DFO was recently characterized in detail by Lu et al. [11], who
calculated a binding constant of 104-105M−1. Analysis of various thermodynamic
parameters indicated that the interaction was likely to be spontaneous and exothermic under
physiologic conditions. The present results suggest that this binding affinity may allow DFO
to function like the hemin binding proteins albumin and hemopexin in facilitating hemin
release from neural cells [8].
Although enhancement of hemin release may account in part for the neuroprotection
provided by DFO against hemin in this study, lysosomal hemin binding by DFO may also
contribute. DFO is a very hydrophilic compound that has little ability to permeate biological
membranes. However, it does enter cells by fluid phase endocytosis, and subsequently
concentrates in lysosomes without significantly entering the cytosol [32]. Its protective
effect in these cultures could also be mediated by increasing the transit of hemin into
lysosomes, as has previously been reported for ferritin-bound iron [33].
Hemin neurotoxicity may be due to direct oxidative injury and membrane destabilization
[5,28] or iron release after its HO-catalyzed breakdown [29]. In a prior study, we reported
Chen-Roetling et al. Page 4













that the latter mechanism predominated in murine cortical cultures when hemin exposure
was conducted in MEM10 without any added proteins [25]. This conclusion was based on
the consistent protection provided by HO-2 gene knockout and iron chelation. In the present
study, the iron-mediated component of injury was mitigated by the addition of BSA and
apotransferrin to the culture medium [18,30]. Under these conditions, a higher hemin
concentration was required to produce neurotoxicity, and HO inhibition with SnPPIX was
not protective, but rather tended to worsen injury. These results suggest that the effect of HO
activity on hemin neurotoxicity is dependent in part on cellular vulnerability to iron. If the
cellular milieu favors chelation of iron in a manner that prevents its participation in free
radical reactions, then any beneficial effect HO inhibition is likely to be lost. It is
noteworthy that Wang et al. reported that HO-2 gene knockout increased the vulnerability of
rat cortical neurons to hemin in culture medium containing BSA and iron-poor transferrin
[31], which was attributed to reduced hemin catabolism.
Since 55Fe-hemin was used in these experiments, some release of the isotope as nonheme
iron cannot be excluded. However, four lines of evidence suggest that this accounted at most
for a small part of the total signal appearing in the culture medium after washout. First, the
HO inhibitor SnPPIX at concentrations sufficient to block hemin breakdown [21] had a
minimal effect on isotope release alone or in the presence of DFO. Second, the iron chelator
2,2′-dipyridyl, which enhances the cellular export of non-heme iron in this culture system
[24], had no effect. Third, albumin increased isotope release, consistent with observations
that it facilitates hemin export by serving as an extracellular acceptor protein [8,9]. Fourth,
release of the fluorescent hemin analog zinc mesoporphyrin, which is not a substrate for HO
but rather a potent HO inhibitor [27], was quantitatively similar to that of 55Fe-hemin.
The molecular mechanisms that mediate hemin uptake and release in neural and other cell
populations remains undefined, and are worthy topics for future investigation. Although
hemin intercalates directly into cell and organelle membranes, its anionic carboxylate side
chains limit cell entry by passive diffusion [34], indicating a need for transporters to meet
cellular needs and prevent toxicity [35]. Several membrane proteins that bind hemin in vitro
and may serve as importers have recently been identified, including protein coupled folate
transporter/heme carrier protein-1, HRG-1, and FLVCR2 [2,3]. However, due to their
relatively low affinity for hemin and interaction with other ligands, hemin import activity
under normal or pathological conditions has not yet been confirmed. ABCG2 and FLVCR1
are cell membrane proteins with a putative hemin export function [8,9]. Mutation of the
latter has been associated with posterior column ataxia, retinitis pigmentosa, and Diamond-
Blackfan anemia, suggesting that it may have a primary role in regulating heme/hemin
levels in some neuronal populations and erythroid progenitor cells. Delineation of hemin
transport mechanisms in neural cells may lead to the identification of new therapeutic targets
to prevent hemin toxicity after CNS hemorrhage.
Conclusion
Neural cells respond to hemin loading by exporting a significant portion over the subsequent
24 hours. This process is most rapid and complete for neurons, and is increased by the
presence of albumin and deferoxamine in the culture medium. Enhancement of hemin export
may be a novel therapeutic target after hemorrhagic CNS injuries.
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Time course of hemin release from neuron-glia cultures, and effect of HO inhibition. A)
Percentage 55Fe signal in cell lysate and culture medium at indicated time points after 55Fe-
hemin loading; B) Effect of indicated concentrations (μM) of the HO inhibitor tin
protoporphyrin IX (Sn) on percentage isotope release into the culture medium at 4 and 24
hours after 55Fe-hemin loading; C) Percentage of zinc mesoporphyrin fluorescence signal in
cell lysate and culture medium at indicated time points after loading. All values represent
mean ± S.E.M. (*P < 0.05 vs. mean value in corresponding control cultures (CTRL) lacking
tin protoporphyrin IX, Bonferroni multiple comparisons test, n = 6 per condition).
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Comparison of 55Fe-hemin uptake and release in neurons, glia, and microglia. A) 55Fe-
hemin signal (± S.E.M.) in cell lysates of indicated culture types after 2 hour treatment with
5 μM 55Fe-hemin. B–D) % 55Fe signal in cell lysate and culture medium at indicated time
points after 55Fe-hemin loading. ***P < 0.001 vs. mean value in microglia cultures, n = 8–
10/condition).
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Deferoxamine (DFO) increases release of cell hemin. A) Uptake: bars represent mean
cell 55Fe signal in mixed cortical cultures after two hour incubation with 5 μM 55Fe-hemin
alone (CTRL) or with 100 μM DFO or 2,2′-dipyridyl (DP); Release: mean medium 55Fe
signal at 24 hours after 55Fe-hemin washout followed by incubation in medium containing
0.67 mg/ml bovine serum albumin alone (CTRL) or with 100 μM DFO or DP. B)
Medium 55Fe signal at 24 hours after 55Fe-hemin washout followed by incubation in BSA-
free medium alone (CTRL) or with indicated concentrations of DFO. C) As in A, testing the
effect of concomitant treatment with the HO inhibitor tin protoporphyrin IX (Sn, 60 μM) on
enhancement of 55Fe-hemin release by DFO, in medium containing BSA. **P < 0.01, ***P
< 0.001 vs. mean value in corresponding CTRL condition.
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Deferoxamine attenuates hemin neurotoxicity. A) Bars represent mean LDH release (±
S.E.M., n = 10–12/condition) in cultures treated for 24 hours with 10 μM hemin or with 10
μM hemin plus 100 μM DFO, 60 μM tin protoporphyrin IX (Sn) or both DFO and tin
protoporphyrin IX. B) Cultures (n= 6/condition) were treated with indicated concentrations
of hemin for 2 hours without DFO; after hemin washout, cultures were placed into medium
containing or lacking 100 μM DFO. *P < 0.05, **P < 0.01 vs. corresponding condition
treated with hemin without DFO. LDH values are normalized to those in sister cultures
treated with NMDA for 24 hours (=100), which kills all neurons in these cultures. The LDH
signal in controls exposed to washes only was subtracted from all values to calculate the
signal due to hemin toxicity.
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